NCT07749807

Brief Summary

This prospective randomized controlled study will compare two techniques used after percutaneous nephrolithotomy, a procedure for removing kidney stones. Participants with renal stones measuring 2-3 cm will be randomly assigned to either tubeless percutaneous nephrolithotomy with nebulized Glubran 2 used to seal the access tract or conventional percutaneous nephrolithotomy with placement of a nephrostomy tube. The study will evaluate whether the Glubran 2-assisted tubeless technique is safe and effective and whether it can reduce postoperative pain, bleeding, hospital stay, urine leakage, and other complications while maintaining a satisfactory stone-free rate.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
5mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 3, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 6, 2026

Completed
26 days until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

August 6, 2026

Status Verified

August 1, 2026

Enrollment Period

5 months

First QC Date

August 3, 2026

Last Update Submit

August 3, 2026

Conditions

Keywords

Percutaneous nephrolithotomyTubeless percutaneous nephrolithotomyConventional percutaneous nephrolithotomyGlubran 2Cyanoacrylate tissue adhesivePercutaneous tract sealingNephrostomy tubeKidney stonesRenal calculiStone-free ratePostoperative painPostoperative bleeding

Outcome Measures

Primary Outcomes (1)

  • Postoperative Pain Intensity

    Postoperative pain will be assessed using the Visual Analog Scale, ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Scores will be compared between the nebulized Glubran 2-assisted tubeless PCNL group and the conventional PCNL group.

    Within the first 24 hours after surgery

Secondary Outcomes (7)

  • Stone-Free Rate

    At 24 hours after surgery

  • Postoperative Hemoglobin Change

    From baseline before surgery to 24 hours after surgery

  • Blood Transfusion Requirement

    From the end of surgery through 24 hours after surgery

  • Urinary Leakage

    From the end of surgery through 48 hours after surgery

  • Length of Hospital Stay

    From the end of surgery through 30 days after surgery

  • +2 more secondary outcomes

Study Arms (2)

Nebulized Glubran 2-Assisted Tubeless PCNL

EXPERIMENTAL

Participants will undergo percutaneous nephrolithotomy followed by tubeless closure of the percutaneous access tract. After stone removal and confirmation of no significant collecting-system injury, 1 mL of Glubran 2 will be delivered into the tract using a special nebulizing applicator under endoscopic and fluoroscopic guidance. The tract will be temporarily occluded using the balloon of a 16 Fr Foley catheter. No nephrostomy tube will be placed. A 6 Fr double-J ureteral stent may be inserted when clinically indicated.

Procedure: Nebulized Glubran 2-Assisted Tubeless PCNL

Conventional PCNL With Nephrostomy Tube

ACTIVE COMPARATOR

Participants will undergo conventional percutaneous nephrolithotomy. After stone removal, a 24 Fr Nelaton tube will be placed as a nephrostomy tube for postoperative drainage. The nephrostomy tube is planned to be removed after approximately 24 hours, according to the participant's clinical condition. A 6 Fr double-J ureteral stent may be inserted when clinically indicated.

Procedure: Conventional PCNL With Nephrostomy Tube

Interventions

Following stone removal by percutaneous nephrolithotomy, 1 mL of Glubran 2 will be nebulized into the percutaneous access tract using a special applicator under endoscopic and fluoroscopic guidance. The tract will be temporarily occluded using a 16 Fr Foley catheter balloon, and no nephrostomy tube will be placed.

Nebulized Glubran 2-Assisted Tubeless PCNL

Following stone removal by percutaneous nephrolithotomy, a 24 Fr Nelaton tube will be placed as a nephrostomy tube for postoperative drainage and will generally be removed after approximately 24 hours according to the participant's clinical condition.

Conventional PCNL With Nephrostomy Tube

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older.
  • Single or multiple renal stones measuring 2-3 cm.
  • Renal stones located in an anatomical position suitable for percutaneous nephrolithotomy.
  • Participant considered suitable for PCNL under general anesthesia.
  • Ability and willingness to provide written informed consent.

You may not qualify if:

  • Active urinary tract infection.
  • Renal stones in an anomalous kidney.
  • Uncontrolled hypertension.
  • Uncontrolled diabetes mellitus.
  • Uncorrected coagulopathy.
  • Clinically significant arrhythmia.
  • Distal ureteric obstruction.
  • Fixed hip joints preventing appropriate operative positioning.
  • Previous renal surgery.
  • Requirement for more than one percutaneous puncture.
  • Pelvicalyceal system perforation during the procedure.
  • Excessive intraoperative bleeding.
  • Any intraoperative finding requiring nephrostomy tube placement for safety.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha University Hospital

Banhā, Qalyubia Governorate, 13511, Egypt

Location

MeSH Terms

Conditions

Kidney CalculiNephrolithiasisPain, PostoperativePostoperative Hemorrhage

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrolithiasisUrinary CalculiMale Urogenital DiseasesCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic ProcessesPainNeurologic ManifestationsSigns and SymptomsHemorrhage

Central Study Contacts

Saad A Salama, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomly assigned in parallel to either nebulized Glubran 2-assisted tubeless percutaneous nephrolithotomy or conventional percutaneous nephrolithotomy with nephrostomy tube placement.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Urology

Study Record Dates

First Submitted

August 3, 2026

First Posted

August 6, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

August 6, 2026

Record last verified: 2026-08

Locations